Rosalind Advisors’s Nuvation Bio NUVB Stock Holding History

Rosalind Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,451,500	Closed	-$4.31M	–	43
2025 Q1	$4.31M	Buy	+2,451,500	New	+$5.58M	2.1%	17

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rosalind Advisors's NUVB Position: Q2 2025 in Review

Rosalind Advisors sold out of Nuvation Bio (NUVB) in Q2 2025, closing a stake of 2,451,500 shares — an estimated $4.31M sold.

Rosalind Advisors first reported a position in NUVB in Q1 2025 and held it in 1 quarter. The position peaked at $4.31M in Q1 2025. 182 funds tracked by Wall St. Rank hold NUVB as of Q2 2025.

Rosalind Advisors reported no remaining Nuvation Bio position as of Q2 2025 after selling out during the quarter.
Rosalind Advisors sold 2,451,500 Nuvation Bio shares in Q2 2025, an estimated $4.31M.
Rosalind Advisors first reported a position in Nuvation Bio in Q1 2025 and held it in 1 quarter.
Rosalind Advisors's Nuvation Bio position peaked at $4.31M in Q1 2025.
182 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2025.

Based on Rosalind Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.